ARS Pharmaceuticals, Inc. SPRY Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$60.62M-78.6% | -$41.32M-183% | -$51.15M-167% | -$44.88M-259% | -$33.94M-230% | ||
| $397K+41.8% | $417K+1,338% | $391K+1,762% | $279K+1,450% | $280K+2,445% | ||
| $7.42M+40.1% | $5.74M+34.6% | $5.69M+58.4% | $5.37M+59.6% | $5.3M+59.8% | ||
| $839K-25.6% | —— | $14.01M+1,712% | $13.25M— | $1.13M— | ||
| $294K-96.5% | $9.72M+68.6% | $0-100% | $4.78M— | $8.45M— | ||
| $10.32M+147% | —— | $10.96M+153% | $12.81M+318% | $4.17M+210% | ||
| $524K-89.1% | -$284K-104% | -$1.07M-312% | -$4.1M-488% | $4.8M+653% | ||
| -$245K-6,225% | -$151K— | —— | —— | $4K— | ||
| -$61K+71.0% | -$55K-103% | -$55K— | -$30K— | -$210K— | ||
| -$44.95M-10.3% | -$43.49M-204% | -$47.05M-225% | -$39.59M-444% | -$40.74M-507% | ||
| $0-100% | $0-100% | $197K+40.7% | $51K+34.2% | $91K+9.6% | ||
| $14.71M-57.2% | $48.89M-70.1% | $127.42M+207% | $31.38M-64.2% | $34.35M-45.9% | ||
| $42.5M-33.1% | $75M+11.9% | $88.5M+45.1% | $80M+6.7% | $63.5M+15.5% | ||
| $27.79M-4.4% | $24.11M+124% | —— | $48.57M+484% | $29.06M+441% | ||
| $62K-91.4% | $1.78M+16.1% | $479K-29.6% | $2.7M+395% | $725K+181% | ||
| $159K-78.1% | $1.13M-98.4% | $100.05M+14,613% | $2.7M+395% | $725K+181% | ||
| -$17M-55.2% | -$18.24M— | $8.02M— | $11.68M+160% | -$10.95M+26.8% | ||
| $2.29M— | —— | —— | —— | $0— | ||
| $990K-49.5% | $1M-35.0% | $1.09M-40.2% | $1.47M— | $1.96M— | ||
| $524K-89.1% | -$284K-104% | -$1.07M-312% | -$4.1M-488% | $4.8M+653% | ||
| -$245K-6,225% | -$151K— | —— | —— | $4K— | ||
| $14.71M-57.2% | $48.89M-70.1% | $127.42M+207% | $31.38M-64.2% | $34.35M-45.9% | ||
| $42.5M-33.1% | $75M+11.9% | $88.5M+45.1% | $80M+6.7% | $63.5M+15.5% | ||
| $62K-91.4% | $1.78M+16.1% | $479K-29.6% | $2.7M+395% | $725K+181% | ||
| $97K— | —— | —— | —— | $0— | ||
| $2.53M— | —— | —— | —— | $0— | ||
| -$61K+71.0% | -$55K-103% | -$55K— | -$30K— | -$210K— | ||
| -$44.95M-10.1% | -$43.49M-204% | -$47.24M-223% | -$39.64M-442% | -$40.83M-501% | ||
| -$44.95M-10.1% | -$43.49M-204% | -$47.24M-223% | -$39.64M-442% | -$40.83M-501% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does ARS Pharmaceuticals, Inc. generate?
- ARS Pharmaceuticals, Inc. (SPRY) generated -$175.1M in operating cash flow over the trailing twelve months.
- What is ARS Pharmaceuticals, Inc.'s free cash flow?
- After $248.0K of capital expenditures, ARS Pharmaceuticals, Inc.'s free cash flow was -$175.3M over the trailing twelve months, down 732.7% year over year.
- Where does ARS Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from ARS Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
